It has become recognized that an important mechanism of tissue repair and functional improvement by stem cells occurs through the release of therapeutic factors (growth factors, chemokines, cytokines, and others) after injection of mesenchymal stem cells (MSCs). Based on their deep understanding of this paracrine mechanism NeuroFx scientific founders Drs. Keith March, MD, PhD and Yansheng Du, PhD of the Indiana University School of Medicine have investigated the potential use of these soluble factors as a therapeutic product to treat disease in humans.
As shown in the graphic below, the therapeutic (soluble) factors secreted by stem cells have been shown to exert multiple beneficial effects including pro-angiogenic, pro-neurogenic, anti-apoptotic, and anti-inflammatory effects.
Theratome Bio is developing a patented therapeutic factor concentrate derived from adult adipose tissue to treat neurological conditions. This Therapeutic Factor Concentrate harnesses the healing potential of adult stem cells to address possible therapeutic and practical shortcomings of stem cell therapies. Potential benefits include immediate bioavailability of growth factors, lowered risk of immunogenicity with repetitive dosing, lower cost of manufacturing, and eliminating the need for storage in cryogenic conditions.
Human trials of Theratome Bio’s lead asset Thera-101 are being planned for 2018.